Responding to the Challenge of Antimalarial Drug Resistance by Routine Monitoring to Update National Malaria Treatment Policies
The DOI matches its Crossref record.
Abstract
Reduced sensitivity of Plasmodium falciparum to formerly recommended cheap and well-known antimalarial drugs places an increasing burden on malaria control programs and national health systems in endemic countries. The high costs of the new artemisinin-based combination treatments underline the use of rational and updated malaria treatment policies, but defining and updating such policies requires a sufficient volume of high-quality drug-resistance data collected at national and regional levels. Three main tools are used for drug resistance monitoring, including therapeutic efficacy tests, in vitro tests, and analyses of molecular markers. Data obtained with the therapeutic efficacy test conducted according to the standard protocol of the World Health Organization are most useful for updating national treatment policies, while the in vitro test and molecular markers can provide important additional information about changing patterns of resistance. However, some of the tests are technically demanding, and thus there is a need for more resources for training and capacity building in endemic countries to be able to adequately respond to the challenge of drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Artemether-lumefantrine (Coartem®) (AL) is a widely accepted artemisinin-based combination therapy (ACT) due to the emergence of resistance to previously commonly used drugs, such as chloroquine and sulphadoxine-pyrimethamine [6–10].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 21
- 1998, 92, 449
- 2004, 48, 4075
- 2002, 360, 58
- 2001, 45, 3122
- 2004, 48, 2214
- 2003, 8, 860
- 1997, 56, 621
- 2003, 19, 175
- 2003, 16, 553
- 2004, 364, 438
- 2000, 108, 13
- 2003, 17, 85
- 2004, 3, 14
- 2005, 72, 155
- 2003, 47, 1347
- 2003, 361, 1174
- 1998, 14, 462
- 2001, 6, 891
- 2004, 190, 853
- 2003, 97, 226
- 2003, 68, 413
Cited by
Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria
Eastman, R. T., & Fidock, D. A. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2239 · Cited by 568
Taylor, S. M., Parobek, C. M., DeConti, D. K., Kayentao, K., Coulibaly, S. O., Greenwood, B. M., Tagbor, H., Williams, J., Bojang, K., Njie, F., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu467 · Cited by 283
Meankaew, P., Kaewkungwal, J., Khamsiriwatchara, A., Khunthong, P., Singhasivanon, P., & Satimai, W. (2010) · Malaria Journal · doi:10.1186/1475-2875-9-237 · Cited by 85
“Strategies to promote patient adherence would improve drug performance and thereby might help to prevent the rapid emergence of drug resistance [24,25].”
BackgroundEbstie, Y. A., Zeynudin, A., Belachew, T., Desalegn, Z., & Suleman, S. (2015) · Malaria Journal · doi:10.1186/s12936-015-0744-x · Cited by 24
Metadata
- Authors
- Vestergaard, L. S., & Ringwald, P.
- Venue
- The American Journal of Tropical Medicine and Hygiene
- Published
- 2007-12
- Volume
- 77
- Issue
- 6_Suppl
- Pages
- 153-159
- ISSN
- 0002-9637
- Cited by
- 60
- References
- 0
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Responding to the Challenge of Antimalarial Drug Resistance by Routine Monitoring to Update National Malaria Treatment Policies. https://app.cochat.ai/papers/10.4269/ajtmh.2007.77.153
- The paper
- Vestergaard, L. S., & Ringwald, P. (2007). Responding to the Challenge of Antimalarial Drug Resistance by Routine Monitoring to Update National Malaria Treatment Policies. The American Journal of Tropical Medicine and Hygiene. https://doi.org/10.4269/ajtmh.2007.77.153
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.